Omzo vs RxActivate: Pricing Transparency and Compounded Medications
Comparing Omzo vs RxActivate: Omzo lists personalized compounded semaglutide starting at $179 with clinician-guided plans, while RxActivate requires completion of a medical eligibility questionnaire and contact information before revealing any price. Verdict: Omzo shows a starting price and explicit compounded-medication program details; RxActivate keeps pricing gated behind intake.
Start Omzo assessment and view pricing
Key difference 1: Pricing transparency and how you see costs
Omzo provides a visible starting price of $179 for semaglutide and $279 for tirzepatide and states medication costs are included in fees collected by Omzo. RxActivate does not display any price or billing terms before users submit contact information. The RxActivate flow displays likely eligibility then requires first name, last name, email and phone number before revealing plans or price.
Begin RxActivate eligibility flow
Key difference 2: Compounded medication programs and regulatory notes
Both providers reference compounded medications when offered. Omzo explicitly describes a Compounded Medication Program prepared by state-licensed sterile compounding pharmacies and states these compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. RxActivate notes that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. These regulatory qualifiers are present for both but Omzo includes more detail about production and provider responsibility.
Learn how Omzo handles compounded meds
Key difference 3: Clinician guidance and intake process
Omzo connects users with licensed U.S. providers who review clinician-guided plans and determine eligibility, and it emphasizes that providers make the final determination as to whether to prescribe medication. RxActivate uses a two-minute eligibility questionnaire and clinician-matching; the flow requests goal, height, weight, target weight, timeline, medication history, sex assigned at birth, date of birth, state and safety screening and then requires contact information to continue. Both require a licensed clinician to determine medical appropriateness, but RxActivate gates plan details behind intake while Omzo shows program options and the clinician-reviewed nature up front.
Key difference 4: Availability, state screening, and membership claims
RxActivate states a large member count on its page and confirmed Alabama was serviceable in a synthetic test; it stresses state and medical-safety screening in the eligibility flow. Omzo warns that pricing, eligibility, pharmacy, state coverage and renewal terms may change and tells users to confirm eligibility, medication, total cost, renewal terms and state availability before enrollment. Both advise confirming state availability and clinician-determined eligibility.
Comparison table: Omzo vs RxActivate
| Criteria | Omzo | RxActivate |
|---|---|---|
| Pricing visibility | Semaglutide starting at $179; tirzepatide starting at $279 | No price shown before contact-info gate |
| Compounded meds | Compounded program from state-licensed sterile compounding pharmacies; not FDA-approved | Compounded meds not FDA-approved when offered; approval status must be confirmed |
| Clinician review | Clinician-guided plans reviewed by licensed U.S. providers | Clinician-matched plans after two-minute questionnaire and screening |
| Intake process | Platform connects to providers; program details visible | Eligibility quiz then requires name, email and phone before plans or price |
| State availability | Users must confirm state availability; terms may change | State and medical-safety screening; Alabama confirmed serviceable in test |
What the evidence does and does not show
The supplied evidence documents Omzo’s publicly displayed starting prices, detailed description of a compounded medication program, and clinician-guided plan language. The evidence shows RxActivate requires an eligibility flow and contact information before disclosing pricing or plan details. The sources include regulatory qualifiers that compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. The sources do not supply independent clinical outcome data or definitive comparisons of efficacy. Do not assume availability, pricing, or prescribing until confirmed with each provider.
Final comparison and short verdict
Omzo vs RxActivate boils down to visibility versus gated intake. If you want an upfront starting price and explicit statements about a compounded program and clinician-reviewed plans, the supplied evidence points to Omzo. If you prefer to go through a short eligibility questionnaire and provide contact details to learn specific plan and price options, the supplied evidence describes RxActivate’s gated approach.
Complete RxActivate quiz to see offers
See Omzo starting prices and options
Choose guidance
Choose Omzo if you need visible starting pricing (semaglutide starting at $179), explicit details about a compounded medication program produced by state-licensed compounding pharmacies, and clinician-guided plans reviewed by licensed U.S. providers. Choose RxActivate if you are comfortable completing a two-minute eligibility questionnaire and submitting contact information to view specific plan pricing and clinician-matched options. In all cases confirm eligibility, medication, total cost, renewal terms and state availability directly with the provider.